These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36721215)

  • 1. Developing guidance for a risk-proportionate approach to blinding statisticians within clinical trials: a mixed methods study.
    Iflaifel M; Sprange K; Bell J; Cook A; Gamble C; Julious SA; Juszczak E; Linsell L; Montgomery A; Partlett C
    Trials; 2023 Jan; 24(1):71. PubMed ID: 36721215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blinding of study statisticians in clinical trials: a qualitative study in UK clinical trials units.
    Iflaifel M; Partlett C; Bell J; Cook A; Gamble C; Julious S; Juszczak E; Linsell L; Montgomery A; Sprange K
    Trials; 2022 Jun; 23(1):535. PubMed ID: 35761345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unblinding of statisticians in clinical trials: commentary on Iflaifel et al., Trials 2023.
    Parker RA
    Trials; 2023 Sep; 24(1):579. PubMed ID: 37691093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participation in environmental enhancement and conservation activities for health and well-being in adults: a review of quantitative and qualitative evidence.
    Husk K; Lovell R; Cooper C; Stahl-Timmins W; Garside R
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD010351. PubMed ID: 27207731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using digital tools in the recruitment and retention in randomised controlled trials: survey of UK Clinical Trial Units and a qualitative study.
    Blatch-Jones A; Nuttall J; Bull A; Worswick L; Mullee M; Peveler R; Falk S; Tape N; Hinks J; Lane AJ; Wyatt JC; Griffiths G
    Trials; 2020 Apr; 21(1):304. PubMed ID: 32245506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials.
    Gamble C; Krishan A; Stocken D; Lewis S; Juszczak E; Doré C; Williamson PR; Altman DG; Montgomery A; Lim P; Berlin J; Senn S; Day S; Barbachano Y; Loder E
    JAMA; 2017 Dec; 318(23):2337-2343. PubMed ID: 29260229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol.
    Retzer A; Keeley T; Ahmed K; Armes J; Brown JM; Calman L; Copland C; Efficace F; Gavin A; Glaser A; Greenfield DM; Lanceley A; Taylor RM; Velikova G; Brundage M; Mercieca-Bebber R; King MT; Calvert M; Kyte D
    BMJ Open; 2018 Feb; 8(2):e017282. PubMed ID: 29431123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups?
    Feys F; Bekkering GE; Singh K; Devroey D
    Syst Rev; 2014 Feb; 3():14. PubMed ID: 24555576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recording harms in randomised controlled trials of behaviour change interventions: a qualitative study of UK clinical trials units and NIHR trial investigators.
    Papaioannou D; Sprange K; Hamer-Kiwacz S; Mooney C; Moody G; Cooper C
    Trials; 2024 Mar; 25(1):163. PubMed ID: 38438935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding current practice, identifying barriers and exploring priorities for adverse event analysis in randomised controlled trials: an online, cross-sectional survey of statisticians from academia and industry.
    Phillips R; Cornelius V
    BMJ Open; 2020 Jun; 10(6):e036875. PubMed ID: 32532777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
    McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
    Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA
    Cook JA; Julious SA; Sones W; Hampson LV; Hewitt C; Berlin JA; Ashby D; Emsley R; Fergusson DA; Walters SJ; Wilson EC; MacLennan G; Stallard N; Rothwell JC; Bland M; Brown L; Ramsay CR; Cook A; Armstrong D; Altman D; Vale LD
    Health Technol Assess; 2019 Oct; 23(60):1-88. PubMed ID: 31661431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.
    Turner L; Shamseer L; Altman DG; Weeks L; Peters J; Kober T; Dias S; Schulz KF; Plint AC; Moher D
    Cochrane Database Syst Rev; 2012 Nov; 11(11):MR000030. PubMed ID: 23152285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
    Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
    Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining a risk-proportionate approach to the validation of statistical programming for clinical trials.
    Gamble C; Lewis S; Stocken D; Juszczak E; Bradburn M; Doré C; Kean S
    Clin Trials; 2024 Feb; 21(1):85-94. PubMed ID: 37957825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.